REG - C4X Discovery - Grant of Options and Directors Dealing

C4X Discovery HoldingsAnnouncement

29/09/2023 11:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230929:nRSc1891Oa&default-theme=true

RNS Number : 1891O  C4X Discovery Holdings PLC  29 September 2023

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

Grant of Options and Directors Dealing

 

29 September 2023 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, today announces that a total of 5,950,000 options over
ordinary shares of the Company were awarded pursuant to the 2014 Share Option
Plan to certain employees, which includes 400,000 options each to Dr Clive
Dix, Chief Executive Officer, Brad Hoy, Chief Financial Officer and Bhavna
Hunjan, Chief Business Officer as set out below.

 

 Director       Position                 Number of share options awarded  Option exercise price per share (pence)  Total number of options held
 Dr Clive Dix   Chief Executive Officer  400,000                          15.1                                     1,245,000
 Brad Hoy       Chief Financial Officer  400,000                          15.1                                     1,400,000
 Bhavna Hunjan  Chief Business Officer   400,000                          15.1                                     1,255,556

 

The options have an exercise price of 15.1 pence, being the average 5-day VWAP
of the ordinary shares prior to the 29 September 2023.  The options can be
exercised at any time between three and ten years of them being granted.

 

The notification below, made in accordance with the requirements of the UK
Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by person discharging
managerial responsibilities and persons closely associated with them.

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name(s)                                                      Dr Clive Dix

 2   Reason for the notification
 a)  Position/status                                              Chief Executive Officer, Director

 b)  Initial notification/Amendment                               Initial Notification

 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         C4X Discovery Holdings plc
 b)  LEI                                                          213800UHNL82E323O870
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Options over ordinary shares of one penny (£0.01) each in the share capital

                                                            of the Company - EMI 2014 Plan

     Identification code

                                                                  ISIN GB00BQQ2RV18
 b)  Nature of the transaction                                    Grant of options over ordinary shares

 c)  Price(s) and volume(s)                                       Price(s)  Volume(s)

                                                            15.1p     400,000

 

 d)  Aggregated information

 e)  Date of the transaction                                      29 September 2023

 f)  Place of the transaction                                     London Stock Exchange - AIM

 

d)

Aggregated information

 

e)

Date of the transaction

 

29 September 2023

f)

Place of the transaction

London Stock Exchange - AIM

 

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Brad Hoy

 2   Reason for the notification
 a)  Position/status                                              Chief Financial Officer, Director

 b)  Initial notification/Amendment                               Initial Notification

 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         C4X Discovery Holdings plc
 b)  LEI                                                          213800UHNL82E323O870
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Options over ordinary shares of one penny (£0.01) each in the share capital

                                                            of the Company - EMI 2014 Plan

     Identification code

                                                                  ISIN GB00BQQ2RV18
 b)  Nature of the transaction                                    Grant of options over ordinary shares

 c)  Price(s) and volume(s)                                       Price(s)  Volume(s)

                                                            15.1p     400,000

 

 d)  Aggregated information

 e)  Date of the transaction                                      29 September 2023

 f)  Place of the transaction                                     London Stock Exchange - AIM

 

d)

Aggregated information

 

e)

Date of the transaction

 

29 September 2023

f)

Place of the transaction

 

London Stock Exchange - AIM

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Bhavna Hunjan

 2   Reason for the notification
 a)  Position/status                                              Chief Business Officer, Director

 b)  Initial notification/Amendment                               Initial Notification

 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         C4X Discovery Holdings plc
 b)  LEI                                                          213800UHNL82E323O870
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Options over ordinary shares of one penny (£0.01) each in the share capital

                                                            of the Company - EMI 2014 Plan

     Identification code

                                                                  ISIN GB00BQQ2RV18
 b)  Nature of the transaction                                    Grant of options over ordinary shares

 c)  Price(s) and volume(s)                                       Price(s)  Volume(s)

                                                            15.1p     400,000

 

 d)  Aggregated information

 e)  Date of the transaction                                      29 September 2023

 f)  Place of the transaction                                     London Stock Exchange - AIM

 

d)

Aggregated information

 

e)

Date of the transaction

 

29 September 2023

f)

Place of the transaction

London Stock Exchange - AIM

 

- Ends -

 

Contacts

 

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)            +44 (0)20 7886 2500
 Rupert Dearden (Corporate Broking)

 C4X Discovery Media - Consilium Strategic Communications
 Mary-Jane Elliott, Chris Gardner, Matthew Neal            +44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining
scientific expertise with cutting-edge Drug Discovery technologies to
efficiently deliver world leading medicines, which are developed by our
partners for the benefit of patients. We have a highly valuable and
differentiated approach to Drug Discovery through our enhanced DNA-based
target identification and candidate molecule design capabilities, generating
small molecule drug candidates across multiple disease areas including
inflammation, oncology, neurodegeneration and addictive disorders. Our
commercially attractive portfolio ranges from early-stage novel target
opportunities to late-stage Drug Discovery programmes ready for out-licensing
to partners and we have two commercially partnered programmes with one
candidate in clinical development.

 

We collaborate with leading pharmaceutical and life sciences companies to
enrich our expertise and take our assets through pre-clinical and clinical
development. Through early-stage revenue-generating licensing deals, we
realise returns from our high value pre-clinical assets which are reinvested
to maximise the value of our Drug Discovery portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUKARROUUKUAR